GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » PS Ratio

Orchestra BioMed Holdings (Orchestra BioMed Holdings) PS Ratio : 79.03 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Orchestra BioMed Holdings's share price is $4.90. Orchestra BioMed Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.06. Hence, Orchestra BioMed Holdings's PS Ratio for today is 79.03.

The historical rank and industry rank for Orchestra BioMed Holdings's PS Ratio or its related term are showing as below:

OBIO' s PS Ratio Range Over the Past 10 Years
Min: 38.07   Med: 69.13   Max: 168.74
Current: 60.89

During the past 4 years, Orchestra BioMed Holdings's highest PS Ratio was 168.74. The lowest was 38.07. And the median was 69.13.

OBIO's PS Ratio is ranked worse than
80.6% of 1000 companies
in the Biotechnology industry
Industry Median: 9.125 vs OBIO: 60.89

Orchestra BioMed Holdings's Revenue per Sharefor the three months ended in Mar. 2024 was $0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.06.

Warning Sign:

Orchestra BioMed Holdings Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Orchestra BioMed Holdings was -25.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -22.70% per year.

During the past 4 years, Orchestra BioMed Holdings's highest 3-Year average Revenue per Share Growth Rate was -22.70% per year. The lowest was -22.70% per year. And the median was -22.70% per year.

Back to Basics: PS Ratio


Orchestra BioMed Holdings PS Ratio Historical Data

The historical data trend for Orchestra BioMed Holdings's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings PS Ratio Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
PS Ratio
- - - 110.00

Orchestra BioMed Holdings Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 154.09 50.00 75.83 110.00 -

Competitive Comparison of Orchestra BioMed Holdings's PS Ratio

For the Biotechnology subindustry, Orchestra BioMed Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchestra BioMed Holdings's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's PS Ratio falls into.



Orchestra BioMed Holdings PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Orchestra BioMed Holdings's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=4.90/0.062
=79.03

Orchestra BioMed Holdings's Share Price of today is $4.90.
Orchestra BioMed Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Orchestra BioMed Holdings  (NAS:OBIO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Orchestra BioMed Holdings PS Ratio Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Traded in Other Exchanges
N/A
Address
150 Union Square Drive,, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Executives
George Papandreou officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain director ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman director, officer: See Remarks 15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello officer: Principal Accounting Officer 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika officer: See Remarks 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman director, officer: See Remarks C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic 10 percent owner 20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan officer: Chief Financial Officer KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith director 6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014